Clinical Trial Update: A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial assessing etrolizumab for maintenance of disease remission in tumor necrosis factor inhibitor-naive ulcerative colitis patients; completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Etrolizumab (etrolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Colitis, Ulcerative | Phase 3 | Status: COMPLETED | Results posted: 2021-06-15